1. Home
  2. STVN vs MDGL Comparison

STVN vs MDGL Comparison

Compare STVN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • MDGL
  • Stock Information
  • Founded
  • STVN 1949
  • MDGL 2011
  • Country
  • STVN Italy
  • MDGL United States
  • Employees
  • STVN N/A
  • MDGL 528
  • Industry
  • STVN Containers/Packaging
  • MDGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • STVN Consumer Discretionary
  • MDGL Health Care
  • Exchange
  • STVN Nasdaq
  • MDGL Nasdaq
  • Market Cap
  • STVN 5.7B
  • MDGL 6.8B
  • IPO Year
  • STVN 2021
  • MDGL N/A
  • Fundamental
  • Price
  • STVN $21.77
  • MDGL $301.58
  • Analyst Decision
  • STVN Buy
  • MDGL Buy
  • Analyst Count
  • STVN 6
  • MDGL 10
  • Target Price
  • STVN $25.08
  • MDGL $354.75
  • AVG Volume (30 Days)
  • STVN 338.6K
  • MDGL 335.7K
  • Earning Date
  • STVN 05-08-2025
  • MDGL 05-01-2025
  • Dividend Yield
  • STVN 0.27%
  • MDGL N/A
  • EPS Growth
  • STVN N/A
  • MDGL N/A
  • EPS
  • STVN 0.45
  • MDGL N/A
  • Revenue
  • STVN $1,143,012,735.00
  • MDGL $180,133,000.00
  • Revenue This Year
  • STVN $8.60
  • MDGL $228.41
  • Revenue Next Year
  • STVN $10.43
  • MDGL $73.44
  • P/E Ratio
  • STVN $48.77
  • MDGL N/A
  • Revenue Growth
  • STVN 1.72
  • MDGL N/A
  • 52 Week Low
  • STVN $16.56
  • MDGL $189.00
  • 52 Week High
  • STVN $28.77
  • MDGL $377.46
  • Technical
  • Relative Strength Index (RSI)
  • STVN 56.72
  • MDGL 42.32
  • Support Level
  • STVN $21.13
  • MDGL $276.20
  • Resistance Level
  • STVN $22.46
  • MDGL $316.18
  • Average True Range (ATR)
  • STVN 1.33
  • MDGL 20.04
  • MACD
  • STVN 0.12
  • MDGL -1.11
  • Stochastic Oscillator
  • STVN 86.32
  • MDGL 44.43

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: